



NDA 22-134

NDA APPROVAL

Vistakon Pharmaceuticals, LLC
Attention: Stephen Holcroft
Vice President Worldwide Regulatory and Clinical Affairs
7500 Centurion Parkway, Suite 100
Jacksonville, FL 32256

Dear Mr. Holcroft:

Please refer to your New Drug Application (NDA) dated September 28, 2009, received September 29, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lastacraft (alcaftadine ophthalmic solution) 0.25%.

We acknowledge receipt of your amendments dated October 6, and 28, November 17, and 19, and December 10, 2009; and January 4, 28, and 29, February 25, March 4, 23, and 31, April 15, 22, and 29, May 3, 7 (2), 12, 26, and 28, June 10, and 25, and July 7, 8, 20, and 22, 2010.

This new drug application provides for the use of Lastacraft (alcaftadine ophthalmic solution) 0.25% for the prevention of itching associated with allergic conjunctivitis.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Submit final printed carton and container labels that are identical to the enclosed carton and container labels, submitted on July 20 and 22, 2010, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled "Providing Regulatory Submissions in Electronic Format – Human

Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 22-134.**”

Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Your application for Lastacraft (alcaftadine ophthalmic solution) 0.25% was not referred to an FDA advisory committee because there are a number of other approved ophthalmic products in this class of drugs with this indication, evaluation of the safety data did not reveal particular safety concerns that were unexpected for the class with topical ophthalmic use, and the design and results of the efficacy trials did not pose particular concerns.

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable. We are waiving the pediatric study requirement for ages 0 month to 24 months because studies are impossible or highly impractical because the number of pediatric patients under 24 months with allergic conjunctivitis is so small. The product is adequately labeled for pediatric patients above the age of 2 years.

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA, to CDERMedWatchSafetyAlerts@fda.hhs.gov, and to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at <http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>.

New molecular entities and new biologics qualify for a post-action feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call Raphael Rodriguez, Regulatory Project Manager, at (301) 796-0798.

Sincerely,

{See appended electronic signature page}

John J. Farley, M.D., M.P.H.
Deputy Director
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
Carton and Container Labeling

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-22134	ORIG-1	VISTAKON PHARMACEUTICA LS LLC	Lastacaft (alcaftadine ophthalmic solution) 0.25%

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOHN J FARLEY
07/28/2010